Zegerid deal solidifies
This article was originally published in The Tan Sheet
Executive Summary
A Santarus license agreement with Schering-Plough for OTC commercialization rights to its immediate-release omeprazole product Zegerid is now effective, as the waiting period required under antitrust law has expired, the firm announces Nov. 21. Santarus expects the proton pump inhibitor's quick action to give it a competitive advantage over P&G's Prilsoec OTC if S-P can gain approval for an Rx-to-OTC switch. The agreement includes a $15 mil. upfront license fee and up to $65 mil. in additional milestone payments (1"The Tan Sheet" Oct. 23, 2006, p. 3)...
You may also be interested in...
Zegerid May Bring Quick Heartburn Relief To Market Under Santarus/S-P deal
Immediate-release delivery will give Santarus' proton pump inhibitor Zegerid (omeprazole/sodium bicarbonate) an edge against Prilosec OTC in the heartburn market if the firm can pull off a planned Rx-to OTC switch
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.